Hämostase bei gestörter Leberfunktion

LITERATUR
1 Abildgaard FCh. Hazards of prothrombin-complex concentrates in treatment of hemophilia. New Engl. J. Med. 304: 670 1981;
2 Aoki N, Yamanaka T. The a₂-plasmin inhibitor levels in liver diseases. Clin. Chim. Acta. 84: 99 1978;
3 Aurousseau M. H, Angeli J. L, Josso F. Antithrombin III versus prothrombin in liver cirrhosis. Haemostasis. 10: 104 1981;
4 Baele G, Matthies E, Barbier F. Antihaemophilic factor A activity, F VIII-related antigen and von Willebrand factor in hepatic cirrhosis. Acta haematol. 57: 290 1977;
5 Barckow D, Schwigon C. D, Sultie J. W. Die Wirksamkeit von Vitamin K zur Therapie und Prophylaxe Moxalactaminduzierter Hypoprothrombinämien. Umweltmedizin. 04: 68 1984;
6 Bechthold H, Andrassy K, Jähnchen E, Koderisch J, Koderisch H, Weilemann L. S, Sonntag H. G, Ritz E. Evidence for impaired hepatic vitamin K! metabolism in patients treated with N-Methyl-Thiotetrazole Cephalosporins. Thromb. Haemostas. 51: 358 1984;
7 Bechthold H, Weilemann L. S, Lorenz J, Andrassy K, Frank D, Meinertz T, Jähnchen E. Cumarinähnliche Wirkung von Cephalosporinen. Verh. Dt. Ges. Inn. Med. 90: 953 1984;
8 Bick R. L, Bick M. D, Fekete L. F. Antithrombin III patterns in disseminated intravascular coagulation. Amer. J. Clin. Path. 04: 577 1980;
9 Biland L, Duckert F, Prisender S, Nymann D. Quantitative estimation of coagulation factors in liver disease. The diagnostic und prognostic value of factor XIII, factor V and plasminogen. Thromb. Haemostas. 39: 646 1978;
10 Birgens H. S, Henriksen J, Mathen P, Poulsen H. The shock liver. Acta Med. Scand. 204: 417 1978;
11 Blanchard R. A, Furie B. C, Jörgensen M, Gruger S. F, Furie B. Acquired vitamin K-dependent carboxylation deficiency in liver disease. New Engl. J. Med. 305: 242 1981;
12 Blatt P. M, Lundblad R. L, Kingdon H, Roberts H. K. Thrombogenic materials in prothrombin complex concentrates. Ann. intern. Med. 81: 766 1972;
13 Bloom A. L. Intravascular coagulation and the liver. Brit. J. Haemat. 30: 1 1975;
14 Brunswig D, Liehr H, Richter E. Verbrauchskoagulopathie bei toxischer Leberschädigung durch Knollenblätterpilzvergiftung. Dtsch. med. Wschr. 97: 1347 1972;
15 Brunswig D. Hepatologische Aspekte des FVIII-assoziierten Antigens. Habilschrift Würzburg. 1976
16 Clark R, Borirakchangavat V, Gazzard B. G, Rake M. O, Shilkin K. B, Flute P. T, Williams R. Disordered hemostasis in liver damage from paracetamol overdose. Gastroenterology. 65: 788 1973;
17 Coccheri S, Palereti G, Dalmonte P. R, Poggi M, Boggian O. Investigations on intravascular coagulation in liver disease: soluble fibrin monomer complexes in liver cirrhosis. Haemostasis. 08: 8 1979;
18 Colombi A. Early diagnosis of fatal hepatitis. Digestion. 03: 129 1970;
19 Cordova C, Musca A, Violi F, Alessandri C, Vezza E. Improvement of some blood coagulation factors in cirrhotic patients treated with low doses of heparin. Scand. J. Haematol. 29: 235 1982;
20 Cordova C, Musca A, Violi F, Alessandri C, Ferro D, Piromalli A, Balsano F. Prekallikrein behaviour in chronic active hepatitis and in cirrhotic patients. Haemostasis. 14: 218 1984;
21 Corrigan J. J, Jeter M, Earnest D. L. Prothrombin antigen and coagulant activity in patients with liver disease. JAMA. 248: 1736 1982;
22 Doody P. T. Disopyramide hepatotoxicity and disseminated intravascular coagulation. South Med. J. 75: 496 1982;
23 Dymock J. W, Tucken J. S, Woolf J. L, Poller L, Thomson J. M. Coagulation studies as a prognostic index in acute liver failure. Brit. J. Haemat. 29: 385 1975;
24 Francis J. L, Armstrong D. J. Fibrinogen-bound sialic acid levels in the dysfibrinogenaemia of liver disease. Haemostasis. 11: 215 1982;
25 Francis J. L, Armstrong D. J. Acquired dysfibrinogenaemia in liver disease. J. Clin. Path. 35: 667 1982;
26 Francis J. L, Sommonds V. L, Armstrong D. J. Fibrinogen-bound sialic acid and liver sialyltransferase activity in an experimental animal model of cirrhosis. Throb. Haemostas. 50: 202 1983;
27 Frick W. Thrombocytopenie und Leberzirrhose. Schweiz. Med. Wschr. 97: 407 1967;
28 Fritsche H. M, Sternberger A, Sommoggy S. v, Fischer M, Blümel G. Zur Pathogenese des Gerinnungsdefektes im akuten Leberversagen. Med. Welt. 32: 390 1981;
29 Fujii M, Yasunaga K, Uchino H. Correlation analysis of relationships between vitamin K-dependent clotting factor and effective hepatic blood flow, albumin and other liver function tests. Haemostasis. 09: 9 1980;
30 Gazzard B. G, Lewis M. L, Ash G, Rizza C. R, Bidwell E, Williams R. Coagulation factor concentrates in the treatment of haemorrhagic diathesis of fulminant hepatic failure. Gut. 15: 993 1974;
31 Gazzard B. G, Clarke R, Borirakchangavat Y, Williams R. A controlled trial of heparin therapy in the coagulation defect of paracetamol induced hepatic necrosis. Gut. 15: 89 1974;
32 Gazzard B. G, Portmann B, Murray-Lyon I. M, Williams R. Courses of death in fulminant hepatic failure and relationship to quantitative histological assessment of parenchymal damage. Q. J. Med. 44: 615 1975;
33 Gazzard B. G, Henderson J. M, Willams R. Factor VII-levels as a guide to prognosis in fulminant hepatic failure. Gut. 17: 489 1976;
34 Girolami A, Padrasti G, Cappellato G, Quaino V. An immunological study of prothrombin in liver cirrhosis. Blut. 41: 41 1980;
35 Green A. J, Ratnoff O. D. Elevated antihaemophilic factor (AHF, factor VIII) procoagulant activity and AHF-like antigen in alcoholic cirrhosis of the liver. J. Lab. Clin. Med. 83: 189 1974;
36 Green G, Poller L, Thomson J. M, Dymock J. W. Factor VII as a marker of hepatocellular synthetic function in liver disease. J. Clin. Path. 29: 971 1976;
37 Green G, Thomson J. M, Dymock I. W, Poller L. Abnormal fibrin polymerization in liver disease. Brit. J. Haematol. 34: 425 1976;
38 Harenberg J, Hepp G, Schmidt-Gayk H. Fibrinopeptide A in human plasmaevaluation of a new radioimmunassay technique on microliter plates. Thromb. Res. 15: 513 1979;
39 Hedner U, Nilsson J. M. Antithrombin III in a clinical material. Thromb. Res. 03: 631 1973;
40 Heene D. L. Gerinnungsstörung bei portaler Hypertension. Z. Gastroent. 13: 147 1975;
41 Hillenbrand P, Parbhoo S. P, Jedrychowski A, Sherlock S. Significance of intravascular coagulation and fibrinolysis in acute hepatic failure. Gut. 15: 83 1974;
42 Hiller E, Hegemann F, Possinger K. Hypercoagulability in acute esophageal variceal bleeding. Thromb. Res. 22: 243 1981;
43 Klingemann H. G, Egbring R, Havemann K. Structure of fibrin and fibrin monomer in renal and hepatic failure. Klin. Wschr. 58: 533 1980;
44 Koj A. Acute-phase reactants their synthesis, turnover and biological significance. In: Allison A. L. Structure and Function of Plasma Proteins. Vol. 1. Plenum Press; London: 1974: 73.
45 Kühn H. A, Liehr H. Systemische Hämodynamik und Blutgerinnung bei portaler Hypertension. Med. Klin. 72: 1713 1977;
46 Kupfer H. G. Statistical correlation of liver function tests with coagulation factor deficiencies in Laenec’s cirrhosis. Thromb. Diath. Haemorrhag. 10: 317 1963;
47 Lasch H. G. Umsatzstörungen der Hämostase bei chronischen Lebererkrankungen. In: Neumayr A. (Hrsg.): Aktuelle Probleme der klinischen Hepatologie. Witzstrock: Baden-Baden; 1975: 63.
48 Lasch H. G, Müller-Berghaus G. Prokontra: Verbrauchskoagulopathie - Heparinbehandlung? Argumente für eine Heparinbehandlung. Internist. 21: 382 1980;
49 Laursen B, Mortensen J. Z, Frist L, Hansen K. B. Disseminated intravascular coagulation in hepatic failure treated with antithrombin III. Thromb. Res. 22: 701 1981;
50 Laursen B, Frost L, Mortensen J. Z, Hansen K. B, Paulsen S. M. Acute fatty liver of pregnancy with complicating disseminated intravascular coagulation. Acta Obstet. Gynecol. Scand. 62: 403 1983;
51 Lenz K, Kleinberger G, Druml W, Laggner A. Die Schockleber. Leber - Magen - Darm. 12: 198 1982;
52 Le Veen H. H, Christoudias G, Moon P, Luft R, Falk G, Grosberg S. Peritoneovenous shunting for ascites. Ann. Surg. 180: 500 1974;
53 Liebmann H. A, McGehee W. G, Patch M. J, Feinstein D. I. Severe depression of AT III associated with disseminated intravascular coagulation in women with fatty liver of pregnancy. Ann. Intern. Med. 98: 330 1983;
54 Lipsky J. J. N-Methyl-thio-tetrazole inhibition of the gamma carboxylation of glutamic acid: possible mechanism for antibiotic-associated hypoprothrombinemia. Lancet. II: 192 1983;
55 Macdougall B. R. D, Bailey R. J, Williams R. H₂-receptor antagonists and antacids in the prevention of acute gastrointestinal haemorrhage in fulminant hepatic failure. Two controlled trialsLancet. I: 617 1977;
56 Mammen E. F. Protein C und S. Hämo- staseologie. 04: 138 1984;
57 Mannucci L, Dioguardi N, Del Nimo E, Mannucci P. M. Value of normotest and antithrombin III in the assessment of liver function. Scand. J. Gastroenterol. 08 (Suppl. 19): 103 1973;
58 Mannucci P. M. Estimation of prothrombin in liver disease. J. Clin. Pathol. 23: 291 1970;
59 Mannucci P. M, Franci F, Dioguardi N. Correction of abnormal coagulation in chronic liver disease by combined use of fresh-frozen plasma and prothrombin complex concentrates. Lancet. II: 542 1976;
60 Mannucci P. M, Vigano S. Deficiencies of protein C, an inhibitor of blood coagulation. Lancet. II: 463 1982;
61 Martinez J, Palascak J. E, Kwasniak D. Abnormal sialic acid content of the dysfibrinogenemia associated with liver disease. J. Clin. Invest 61: 535 1978;
62 Matthias F. R. Umsatzstörungen im Gerinnungs- und Fibrinolysesystem durch Erkrankungen der Leber. Schwerpunktmed. 05: 21 1982;
63 Matthias F. R. Blutgerinnungsstörungen. Hämorrhagische Diathesen und thromboembolische Erkrankungen. Springer, Berlin - Heidelberg: 1985: 113.
64 Neidhardt B, Schricker T. hK. Hämostasestörungen bei Leberzirrhose. Teil 2: Therapie. Fortschr. Med. 100: 836 1982;
65 Oehler G, Bleyl H, Bischoff B, Henk R. Vergleich von Prothrombin-Aktivität und -konzentration bei verschiedenen Funktionszuständen der Leber. Verh. Dtsch. Ges. Inn. Med. 80: 1452 1974;
66 Oehler G, Matthias F. R. Affinitätschromatographische Fibrinmonomer-Bestimmung bei chronischen Lebererkrankungen. Verh. Dtsch. Ges. Inn. Med. 85: 481 1979;
67 Oehler G, Bleyl H, Röka L. Immunologische Prothrombinbestimmung bei Patienten mit Leberkrankheiten. In: Fibrinolyse, Thrombose, Hämostase. Deutsch, E., K. Lechner (Hrsg.). Schattauer, Stuttgart -New York; 1980: 135.
68 Oehler G, Lasch H. G. Gerinnungsstörungen im Schock. In: Handbuch der Inneren Riecker Medizin, G. (Hrsg.). Bd. IX/ 2: Schock.. Springer, Berlin - Heidelberg - New York: 1984: 203.
69 Oehler G, Matthes K. Protein C in various liver diseases. In: Witt J. (Ed.): Protein C. Proceedings of the International Workshop on Biochemical and Medical Aspects of Protein C, Titisee, July 9-11, 1984. de Gruyter. Berlin - New York (im Druck).:
70 Oka K, Tanaka K. Local fibrinolysis of esophagus and stomach as a cause of hemorrhage in liver cirrhosis. Thromb. Res. 14: 837 1979;
71 Orlando M, Casalbore P, Camagna A, Lauro R, Tardella L, Hassan H. J. Factor VII in liver cirrhosis. Haemostasis. 11: 73 1982;
72 Ostermann H, Kirchhoff B, Pott G. Prothrombin determination in plasma and in liver biopsies in chronic liver diseases. Res. exp. med. 180: 271 1982;
73 Pabinger-Fasching J. Protein C - ein in der Leber gebildeter Gerinnungsinhibitor. Hämostaseologie. 04: 50 1984;
74 Pakter R. L, Russel T. R, Meilke C. H, West D. Coagulopathy associated with the use of moxalactam. Jama. 248: 1100 1982;
75 Palascak J. E, Martinez J. Dysfibrinogenemia associated with liver disease. J. Clin. Invest. 60: 89 1977;
76 Ragni M. V, Lewis J. H, Spero J. A, Hariba U. Bleeding and coagulation abnormalities in alcoholic cirrhotic liver disease. Alcoholism. 06: 267 1980;
77 Rake M. O, Flute P. T, Panell G, Williams R. Intravascular coagulation in acute hepatic necrosis. Lancet. I: 533 1970;
78 Ronneberger H, Hein B. Effect of antithrombin III on experimental intoxications with hepatotoxins in dogs. Toxicology Letters. 01: 179 1980;
79 Rubin M. H, Werton M. J, Langley P. G, White Y, Williams R. Platelet function in chronic liver disease. Relation to disease severity. Dig. Dis. Sci. 24: 197 1979;
80 Ruiz F, Grainger S. L, Hall R. J. C, Ingram G. I. C, Pollard V, Swan A. V. Relation of simple clotting tests to clotting factor levels in liver disease. Clin. lab. Haemat. 04: 247 1982;
81 Sbarbaro J. A, Bennett R. M. Aspirin hepatotoxicity and disseminated intravascular coagulation. Ann. intern. Med. 86: 183 1977;
82 Scharf R. E, Schneider W, Heisig S, Schramm W. Thrombozytopenie bei Leberzirrhose. Klin. Wschr. 61: 703 1983;
83 Scharf R. E, Heisig S, Winkelmann M, Schneider W. Erhöhte thrombozytäre Sialinsäurekonzentration bei Leberzirrhose. Verh. Dtsch. Ges. Inn. Med. 89: 990 1983;
84 Schipper G. H, Henkins G. S. P, Kahle L. H, Tencate J. W. AT Ill-transfusion in disseminated intravascular coagulation. Lancet. I: 854 1978;
85 Schneider W, Scharf R. E, Schramm W. Thrombozyten und Lebererkrankungen. Verh. Dtsch. Ges. Inn. Med. 88: 1336 1982;
86 Schuster H. P, Prellwitz W, Schönborn H, Olbermann M. Blutgerinnungsstörungen als Mitursache massiver gastrointestinaler Blutungen bei Patienten mit Leberzirrhose. Med. Welt. 27: 1392 1976;
87 Schwarz M. L, Swame W. R, Vogel S. B. Coagulopathy following peritoneovenous shunting. Surgery. 85: 671 1979;
88 Simert G, Lundequist A, Tylén U. Correlation between percutaneous transhepatic portography and clinical findings in 56 patients with portal hypertension. Acta chir. Scand. 144: 27 1978;
89 Singh R, Singh M. M, Hazra D. K, Agarwal N, Patney N. L, Goyal S. P, Bausal O. P, Mekrotas M. P, Sherma S. K. A study of disseminated intravascular coagulopathy in hepatic coma complicating acute viral hepatitis. Angiology. 34: 470 1983;
90 Soria J, Soria C, Samama M, Coupler J, Girard M. L, Bousser J, Pasquier-Bilski G. Dysfibrinogénémia acquises dans les atteintes hépatiques sévères. Coagulation. 03: 37 1970;
91 Spero J. A, Lewis J. H, Hasiba U. Disseminated intravascular coagulation. Findings in 346 patients. Thrombos. Haemostas. 43: 28 1980;
92 Stein S. F, Harker L. A. Kinetic and functional studies of platelets, fibrinogen and plasminogen in patients with hepatic cirrhosis. J. Lab. Clin. Med. 99: 217 1982;
93 Straub P. W. Diffuse intravascular coagulation in liver disease? Semin. Thromb. Haemostas. 04: 29 1977;
94 Straub P. W. Pro-kontra: Verbrauchskoagulopathie - Heparinbehandlung? Argumente gegen eine Heparinbehandlung. Internist. 21: 385 1980;
95 Tytgat G. N, Collen D, Verstraete M. Metabolism of fibrinogen in cirrhosis of the liver. J. Clin. Invest. 50: 1690 1971;
96 Verstraete M, Vermylen J, Collen D. Intravascular coagulation in liver disease. Ann. Rv. Med. 25: 447 1974;
97 Vogel G. E, Clarmann M. v. Therapie bei Knollenblätterpilzvergiftung. Umweltmedizin. 03: 41 1981;
98 Vogel G. E, Clarmann M. v, Komm C. h, Oberdörfer A. Die Therapie mit Antithrombin III (AT III) beim akuten Leberversagen (ALV). In: Blümel G, Haas S. (Hrsg.): Mikrozirkulation und Prostaglandinstoffwechsel. Verhandlungs- bericht der 25. Tagung der Deutschen Arbeitsgemeinschaft für Blutgerinnungsforschung, München. 1981: 471.
99 Vogel G. E, Komm C. h, Lorenz R, Bottermann P. Das akute Leberversagen - neue therapeutische Aspekte. Intensivbehandlung. 09: 60 1984;
100 Vogel G. E. Substitution von Antithrombin III. Eine neue Therapiemöglichkeit bei schweren Lebererkrankungen. Hämostaseologie. 04: 54 1984;
101 Walker J, Wilner R. A, Johnston M. A, Rand C. A, Neame P. B, Hirsh J. Factors XI and XII are low in subjects with liver disease. Dig. Dis. Sci. 28: 967 1983;
102 Weitekamp M, Aber R. Prolonged bleeding times and bleeding diathesis associated with moxalactam administration. JAMA. 249: 69 1983;
103 Zimmermann R, Czygan P, Harenberg J, Kommereil B. Zur Bedeutung von Antithrombin III bei der hepatischen Hämostasestörung. Inn. Med. 09: 270 1982;
104 Zwierzina W. D, Kunz F, Judmaier G, Mikuz G, Gattringer K. Akute Schwangerschaftsfettleber mit Verbrauchskoagu- lopathie. Dtsch. med. Wschr. 108: 703 1983;